Pretax income is the income that a company earns before paying income taxes. Spero Therapeutics's pretax income for the
three
months ended in Dec. 2024 was €-19.67 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was €-63.63 Mil.
Spero Therapeutics's pretax margin was -220.16%.
During the past 10 years, Spero Therapeutics's highest Pretax Margin was 26.26%. The lowest was -30341.09%. And the median was -767.54%.
Spero Therapeutics Pre-Tax Income Historical Data
The historical data trend for Spero Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spero Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Spero Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-63.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (FRA:2HA) Pre-Tax Income Explanation
Spero Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 10 years, Spero Therapeutics's highest Pretax Margin was 26.26%. The lowest was -30341.09%. And the median was -767.54%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Spero Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:2HA has been successfully added to your 